HomeComparePKBO vs BTI

PKBO vs BTI: Dividend Comparison 2026

PKBO yields 8888.89% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBO wins by $17290949737713800.00M in total portfolio value
10 years
PKBO
PKBO
● Live price
8888.89%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17290949737713800.00M
Annual income
$16,916,578,202,775,594,000,000.00
Full PKBO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — PKBO vs BTI

📍 PKBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBO + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKBO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBO
Annual income on $10K today (after 15% tax)
$755,555.56/yr
After 10yr DRIP, annual income (after tax)
$14,379,091,472,359,256,000,000.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, PKBO beats the other by $14,379,091,472,359,256,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBO + BTI for your $10,000?

PKBO: 50%BTI: 50%
100% BTI50/50100% PKBO
Portfolio after 10yr
$8645474868856900.00M
Annual income
$8,458,289,101,387,797,000,000.00/yr
Blended yield
97.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

PKBO
No analyst data
Altman Z
13837.7
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBO buys
0
BTI buys
0
No recent congressional trades found for PKBO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOBTI
Forward yield8888.89%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$17290949737713800.00M$37.7K
Annual income after 10y$16,916,578,202,775,594,000,000.00$2,786.64
Total dividends collected$17265985963886318.00M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PKBO vs BTI ($10,000, DRIP)

YearPKBO PortfolioPKBO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$899,589$888,888.89$11,299$598.92+$888.3KPKBO
2$75,694,763$74,732,202.61$12,794$703.91+$75.68MPKBO
3$5,957,858,933$5,876,865,536.53$14,518$829.07+$5957.84MPKBO
4$438,676,028,838$432,301,119,780.33$16,513$978.64+$438676.01MPKBO
5$30,217,280,421,144$29,747,897,070,286.80$18,827$1,157.84+$30217280.40MPKBO
6$1,947,399,451,993,550$1,915,066,961,942,926.00$21,518$1,373.12+$1947399451.97MPKBO
7$117,429,004,658,116,600$115,345,287,244,483,520.00$24,657$1,632.46+$117429004658.09MPKBO
8$6,625,994,131,926,989,000$6,500,345,096,942,805,000.00$28,329$1,945.74+$6625994131926.96MPKBO
9$349,879,939,194,586,330,000$342,790,125,473,424,500,000.00$32,637$2,325.33+$349879939194586.31MPKBO
10$17,290,949,737,713,800,000,000$16,916,578,202,775,594,000,000.00$37,708$2,786.64+$17290949737713800.00MPKBO

PKBO vs BTI: Complete Analysis 2026

PKBOStock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBO Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this PKBO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBO vs SCHDPKBO vs JEPIPKBO vs OPKBO vs KOPKBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.